A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma

Annals of Internal Medicine

Volumn 140, Issue 3, 2004, Pages

  Chan, Andrew T ^a   Giovannucci, Edward L ^a   Schernhammer, Eva S ^a   Colditz, Graham A ^a   Hunter, David J ^a   Willett, Walter C ^a   Fuchs, Charles S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADENOMA; ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SELF REPORT;

EID: 0742283971     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-140-3-200402030-00006     Document Type: Article

References (58)

1. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci U S A. 1998;95:681-6. [PMID: 9435252]
2. He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99:335-45. [PMID: 10555149]
3. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956-9. [PMID: 8052854]
4. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, et al. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 2000; 60:6846-50. [PMID: 11156377]
5. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93: 705-16. [PMID: 9630216]
6. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem. 1999;274:27307-14. [PMID: 10480951]
7. Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr A, Breuer N, et al. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion. 2000; 61:129-34. [PMID: 10705177]
8. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology. 2000;11:376-81. [PMID: 10874542]
9. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241-6. [PMID: 8037405]
10. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst. 1993;85:912-6. [PMID: 8492320] .
11. La Vecchia C, Negri E, Franceschi S, Conti E, Montella M, Giacosa A, et al. Aspirin and colorectal cancer. Br J Cancer. 1997;76:675-7. [PMID: 9303370]
12. Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and nonsteroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ. 1993;307:285-9. [PMID: 8374373]
13. Martin C, Connelly A, Keku TO, Mountcasde SB, Galanko J, Woosley JT, et al. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology. 2002;123:1770-7. [PMID: 12454832]
14. Martinez ME, McPherson RS, Levin B, Annegers JF. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev. 1995;4:703-7. [PMID: 8672985]
15. Peleg II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CM. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci. 1996;41:1319-26. [PMID: 8689906]
16. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 1991;83:355-8. [PMID: 1759994]
17. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer. 1998;82:2326-33. [PMID: 9635524]
18. Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology. 1998;114:441-7. [PMID: 9496933]
19. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138-46. [PMID: 8172988]
20. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer. 1993;72:1171-7. [PMID: 8339210]
21. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003; 348:891-9. [PMID: 12621133]
22. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-90. [PMID: 12621132]
23. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609-14. [PMID: 7637720]
24. Chau I, Cunningham D. Cyclooxygenase inhibition in cancer-a blind alley or a new therapeutic reality? [Editorial]. N Engl J Med. 2002;346:1085-7. [PMID: 11932478]
25. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med. 2003;348:879-80. [PMID: 12621130]
26. Chan AT. Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control. 2003;14: 413-8. [PMID: 12946035]
27. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85:1220-4. [PMID: 8331682]
28. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313-6. [PMID: 8385741]
29. Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002;346:1054-9. [PMID: 11932472]
30. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985; 122:51-65. [PMID: 4014201]
31. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991; 266:521-7. [PMID: 2061978]
32. Giovannucci E, Colditz GA, Stampfer MJ, Hunter D, Rosner BA, Willett WC, et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J Natl Cancer Inst. 1994;86:192-9. [PMID: 8283491]
33. Giovannucci E, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control. 1996;7:253-63. [PMID: 8740738]
34. Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med. 1998;129:517-24. [PMID: 9758570]
35. Iso H, Hennekens CH, Stampfer MJ, Rexrode KM, Colditz GA, Speizer FE, et al. Prospective study of aspirin use and risk of stroke in women. Stroke. 1999;30:1764-71. [PMID: 10471421]
36. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York: John Wiley; 2000.
37. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125:328-36. [PMID: 12891533]
38. Tangrea JA, Albert PS, Lanza E, Woodson K, Corle D, Hasson M, et al. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States). Cancer Causes Control. 2003; 14:403-11. [PMID: 12946034]
39. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-52. [PMID: 10874062]
40. Ruffin MT 4th, Krishnan K, Rock CL Normolle D, Vaerten MA, Peters-Golden M, et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst. 1997;89:1152-60. [PMID: 9262254]
41. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119:39S-63S. [PMID: 11157642]
42. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183-8. [PMID: 7926468]
43. Neugut AI, Jacobson JS, Ahsan H, Santos J, Garbowski GC, Forde KA, et al. Incidence and recurrence rates of colorectal adenomas: a prospective study. Gastroenterology. 1995;108:402-8. [PMID: 7835580]
44. Baier M, Calonge N, Cutter G, McClatchey M, Schoentgen S, Hines S, et al. Validity of self-reported colorectal cancer screening behavior. Cancer Epidemiol Biomarkers Prev. 2000;9:229-32. [PMID: 10698488]
45. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122:327-34. [PMID: 7847643]
46. Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med. 1998; 128:705-12. [PMID: 9556463]
47. Rex DK. Colonoscopy: a review of its yield for cancers and adenomas by indication. Am J Gastroenterol. 1995;90:353-65. [PMID: 7872270]
48. Ransohoff DF, Lang CA. Small adenomas detected during fecal occult blood test screening for colorectal cancer. The impact of serendipity. JAMA. 1990;264: 76-8. [PMID: 2192093]
49. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003;124:544-60. [PMID: 12557158]
50. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183-7. [PMID: 11073508]
51. Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol. 1993;35: 219-26. [PMID: 8471398]
52. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827-30. [PMID: 7711618]
53. Slattery J, Warlow CP, Shorrock CJ, Langman MJ. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin-analysis of gastrointestinal bleeding during the UK-TIA trial. Gut. 1995;37:509-11. [PMID: 7489937]
54. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136:157-60. [PMID: 11790071]
55. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest. 1997; 100: 1325-9. [PMID: 9294096]
56. Ladabaum U, Chopra CL, Huang G, Scheiman JM, Chernew ME, Fendrick AM. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med. 2001;135:769-81. [PMID: 11694102]
57. Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology. 2002;122:78-84. [PMID: 11781283]
58. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101:1206-18. [PMID: 10715270]